Ryan O’Keefe: Diagnostic Insights Into High-Risk Myelodysplastic Syndrome
Ryan O’Keefe, Internal Medicine Resident at the Hospital of The University of Pennsylvania, Creator of Point of Care Medicine, shared a post on X:
“Daily Pearl(s):
High-Risk Myelodysplastic Syndrome (MDS) with U2AF1 Mutation.
The triad of unexplained systemic inflammation (high ESR/CRP), progressive cytopenias, and an opportunistic infection (such as candida esophagitis) should raise suspicion for an underlying hematologic malignancy like MDS.
In complex cases with multiple problems, systematically evaluate each one before attempting to unify them – pursuing a red herring as part of a systemic process can be dangerously misleading.
Bilateral adrenal hemorrhage is a medical emergency and can be a rare paraneoplastic manifestation of MDS, which creates a paradoxical state of thrombosis (from inflammation) and hemorrhage (from thrombocytopenia).
Clonal hematopoiesis (MDS, VEXAS syndrome) is an increasingly recognized cause of severe seronegative or atypical autoimmune and vasculitic syndromes, particularly in older adults.
When persistent, unexplained cytopenias and systemic illness remain after extensive infectious and rheumatologic workups, bone marrow biopsy with genetic testing can be a critical diagnostic step.
MDS impairs innate immune function, predisposing patients to opportunistic fungal infections even without classic risk factors like chemotherapy or high-dose steroids.
High-risk MDS is treated with hypomethylating agents (azacitidine) or, in eligible patients, allogeneic stem cell transplantation.
Spliceosome mutations (U2AF1, SF3B1, SRSF2) and UBA1 mutations (VEXAS) are key driver variants to know.
Source: April 11, 2026 Simplicity in Complexity VMR with Jeffrey and Kirtan – dyspnea and vision loss.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention